Document Type



Available under a Creative Commons Attribution Non-Commercial Share Alike 4.0 International Licence



Publication Details

Analytical and Bioanalytical Chemistry, 2011 Jan;399(2):691-700.

Available here


Low molecular weight heparins (LMWHs) are recognised as the preferred anticoagulants in the prevention and treatment of venous thromboembolism. Anti-Factor Xa (anti-FXa) levels are used to monitor the anticoagulant effect of LMWHs and such assays are routinely employed in hospital diagnostic laboratories. In this study, a fluorogenic anti-FXa assay was developed using a commercially available fluorogenic substrate with an attached 6-amino-1- naphthalene-sulfonamide (ANSN) fluorophore and was used for the determination of two LMWHs, enoxaparin and tinzaparin and the heparinoid, danaparoid. The assay was based on the complexation of heparinised plasma with 100 nM exogenous FXa and 25 μM of the fluorogenic substrate Mes-D-LGR-ANSN (C2H5)2 (SN-7). The assay was tested with pooled plasma samples spiked with anticoagulant concentrations in the range 0–1.6 U mL−1. The statistically sensitive assay range was 0–0.4 U mL−1 for enoxaparin and tinzaparin and 0–0.2 U mL−1 for danaparoid, with assay variation typically below 10.5%. This assay was then compared with a previously published fluorogenic anti- FXa assay developed with the peptide substrate, methylsulfonyl-D-cyclohexylalanyl-glycyl-arginine-7-amino- 4-methylcoumarin acetate (Pefafluor FXa). Both assays were compared in terms of fluorescence intensity, lag times and sensitivity to anticoagulants.



Enterprise Ireland

Included in

Biology Commons